Astria Therapeutics (NASDAQ:ATXS) Shares Down 3.4% - Here's What Happened

Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report)'s stock price traded down 3.4% during trading on Thursday . The company traded as low as $9.22 and last traded at $9.22. 20,860 shares were traded during trading, a decline of 96% from the average session volume of 587,191 shares. The stock had previously closed at $9.54.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on ATXS shares. Oppenheimer boosted their target price on shares of Astria Therapeutics from $26.00 to $28.00 and gave the company an "outperform" rating in a research note on Thursday, November 14th. HC Wainwright reissued a "buy" rating and set a $16.00 price objective on shares of Astria Therapeutics in a research note on Tuesday, December 10th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $25.60.

Astria Therapeutics Price Performance

The firm's 50-day moving average price is $10.50 and its 200-day moving average price is $10.71. The company has a market cap of $531.61 million, a price-to-earnings ratio of -4.51 and a beta of 0.67.

Hedge Funds Weigh In On Astria Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ATXS. Quest Partners LLC increased its position in shares of Astria Therapeutics by 3,310.6% during the second quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 3,112 shares during the last quarter. PDT Partners LLC purchased a new stake in Astria Therapeutics during the 3rd quarter worth approximately $140,000. SG Americas Securities LLC acquired a new position in shares of Astria Therapeutics in the 3rd quarter valued at approximately $155,000. Hsbc Holdings PLC bought a new stake in shares of Astria Therapeutics in the second quarter worth $171,000. Finally, Intech Investment Management LLC acquired a new position in Astria Therapeutics in the third quarter worth about $228,000. Institutional investors and hedge funds own 98.98% of the company's stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.